Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
9 analysts rate KRRO Buy on consensus.
Consensus price target: $20.00 (+65.98% upside from $12.05)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Dolan Oliver Senior Vice President, Finance | Sep 9, 2026 | Sale | 6 | $81.62 |
| Dolan Oliver Senior Vice President, Finance | Sep 8, 2026 | Sale | 7,347 | $99.29K |
| FORMELA JEAN FRANCOIS director | Aug 26, 2026 | Sale | 51 | $711.96 |
| FORMELA JEAN FRANCOIS director | Aug 26, 2026 | Sale | 249 | $3.48K |
| FORMELA JEAN FRANCOIS director | Aug 19, 2026 | Sale | 23,584 | $330.18K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $6.39M | +181.46% | $-117.26M |
| 2024 | $2.27M | — | $-83.58M |
| 2023 | $0 | — | $-81.17M |
Stock data for KRRO: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics